Christopher Horan net worth and biography

Christopher Horan Biography and Net Worth

Christopher Horan spent nearly 14 years at Genentech, a member of the Roche Group, where he held several leadership positions across technical operations, including as Senior Vice President, Global Product and Supply Chain Management for Roche in Basel, Switzerland. In that role, he led a 480-person team supplying all of Roche biopharma products worldwide. Mr. Horan joins Artiva from SanBio, where, as Chief Technical Officer (CTO), he led the process development, manufacturing, supply, and quality systems for their mesenchymal stem cell regenerative medicine approach to brain injury in support of a near-term registration in Japan. Previous to SanBio, he was Chief Technical Operations Officer at Dermira, where he led all aspects of pharmaceutical sciences, manufacturing, quality, supply chain, and procurement to launch the company’s first commercial product. He led the effort to prepare Dermira’s IL-13 monoclonal antibody program for Phase 3 trials and commercial filing and had a key role in supporting the company’s successful acquisition by Eli Lilly and Company. Mr. Horan started his career with over a decade of increasing responsibility in technical operations at Merck & Co. He earned a B.E. in engineering from the Stevens Institute of Technology in New Jersey.

What is Christopher Horan's net worth?: The estimated net worth of Christopher Horan is at least $2.88 million as of May 19th, 2026. Horan owns 293,450 shares of Artiva Biotherapeutics stock worth more than $2,881,679 as of June 23rd. This net worth evaluation does not reflect any other investments that Horan may own. Learn More about Christopher Horan's net worth.
How do I contact Christopher Horan?: The corporate mailing address for Horan and other Artiva Biotherapeutics executives is , , . Artiva Biotherapeutics can also be reached via phone at (858) 267-4467 and via email at [email protected]. Learn More on Christopher Horan's contact information.
Has Christopher Horan been buying or selling shares of Artiva Biotherapeutics?: Over the course of the past ninety days, Christopher Horan has sold $63,088.02 in Artiva Biotherapeutics stock. Most recently, Christopher Horan sold 7,002 shares of the business's stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $9.01, for a transaction totalling $63,088.02. Following the completion of the sale, the insider now directly owns 293,450 shares of the company's stock, valued at $2,643,984.50. Learn More on Christopher Horan's trading history.
Who are Artiva Biotherapeutics' active insiders?: Artiva Biotherapeutics' insider roster includes Fred Aslan (President and Chief Executive Officer), Subhashis Banerjee (Insider), Jennifer Bush (COO), Christopher Horan (Insider), and Heather Raymon (SVP). Learn More on Artiva Biotherapeutics' active insiders.
Are insiders buying or selling shares of Artiva Biotherapeutics?: In the last year, Artiva Biotherapeutics insiders bought shares 9 times. They purchased a total of 9,501,755 shares worth more than $103,750,036.39. In the last year, insiders at the sold shares 9 times. They sold a total of 113,602 shares worth more than $741,174.90. The most recent insider tranaction occured on June, 16th when Director Ra Capital Management, L.P. bought 124,893 shares worth more than $1,110,298.77. Insiders at Artiva Biotherapeutics own 21.4% of the company. Learn More about insider trades at Artiva Biotherapeutics.
Information on this page was last updated on 6/16/2026.

Christopher Horan Insider Trading History at Artiva Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/19/2026	Sell	7,002	$9.01	$63,088.02	293,450

Christopher Horan Buying and Selling Activity at Artiva Biotherapeutics

Artiva Biotherapeutics Company Overview

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Today's Range

Now: $9.73

$9.21

$10.00

50 Day Range

MA: $9.26

$6.80

$13.39

2 Week Range

Now: $9.73

$1.47

$14.53

Volume

215,878 shs

Average Volume

372,408 shs

Market Capitalization

$240.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.4